文献速递类风湿关节炎

生物靶向治疗的有效性可能区分血清阴性类风湿关节炎与血清阳性类风湿关节炎

Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该回顾性研究纳入81例血清阴性及404例血清阳性类风湿关节炎患者,评估阿巴西普、抗TNFα或托珠单抗的10年药物生存率。在血清阴性患者中,托珠单抗生存率73.9%显著高于阿巴西普37.5%,抗TNFα居中但差异无统计学意义;血清阳性患者中三种药物生存率无显著差异。

要点

  • 血清阴性RA中托珠单抗10年生存率73.9%,显著高于阿巴西普37.5%(P=0.01)。
  • 抗TNFα在血清阴性RA中生存率50.0%,与另两药差异无统计学意义。
  • 血清阳性RA中三种bDMARD药物生存率无显著差异。

核心结论

  • 在血清阴性RA中,托珠单抗的10年药物生存率显著高于阿巴西普,抗TNFα居中但差异无统计学意义。
  • 血清阳性RA中三种bDMARD药物生存率未见显著差异。
  • 作者认为需在更大队列中开展前瞻性研究以确认这些初步发现并探索血清阴性RA的独特治疗算法。

研究设计与样本

  • 回顾性选择81例血清阴性及404例血清阳性RA患者,接受阿巴西普、抗TNFα或托珠单抗治疗。
  • 采用Kaplan-Meier分析评估10年随访期间的药物生存率,log rank检验比较生存率,多因素Cox回归估计停药风险比(HR)。

主要发现

  • 两组临床特征相似,但血清阴性RA患者既往bDMARD应答不足的比例显著更高(P=0.02)。
  • 血清阴性RA中,托珠单抗生存率73.9%,平均生存时间(MST)76.8个月(95%CI 61-92),显著高于阿巴西普[37.5%,MST 37.1个月(95%CI 22-51;P=0.01)]。
  • 血清阴性RA中,抗TNFα生存率50.0%,MST 63.5个月(95%CI 47-79),与另两药差异无统计学意义。
  • 血清阳性RA患者三种药物生存率无显著差异。
  • 停药负预测因素为RF/ACPA阳性(HR 0.56)和男性(HR 0.58);正预测因素为阿巴西普治疗(HR 1.88)、抗TNFα治疗(HR 1.79)、未联合传统DMARDs(HR 1.74)、无骨侵蚀(HR 1.41)和较高HAQ(HR 1.58)。

关键数值与推荐

  • 血清阴性RA:托珠单抗生存率73.9%,MST 76.8个月(95%CI 61-92)vs 阿巴西普37.5%,MST 37.1个月(95%CI 22-51),P=0.01。
  • 血清阴性RA:抗TNFα生存率50.0%,MST 63.5个月(95%CI 47-79),与另两药差异无统计学意义。
  • 停药负预测因素:RF/ACPA阳性HR 0.56;男性HR 0.58。
  • 停药正预测因素:阿巴西普HR 1.88;抗TNFα HR 1.79;未联合传统DMARDs HR 1.74;无骨侵蚀HR 1.41;较高HAQ HR 1.58。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出这些为初步发现,需在更大队列中开展前瞻性研究以确认并探索血清阴性RA的独特治疗算法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the real-world effectiveness of targeting biologic DMARDs (bDMARDs) in rheumatoid arthritis (RA) patients negative for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). METHODS: We retrospectively selected 81 seronegative and 404 seropositive RA patients receiving treatment with abatacept, anti-TNF alpha or tocilizumab. Effectiveness was evaluated by analysing drug survival using Kaplan-Meyer analysis over 10-year follow-up. Survival rates were compared by log rank test, and hazard ratios (HRs) of therapy discontinuation were estimated through multivariate Cox regression. RESULTS: Clinical characteristics were similar between the two groups, except for a significantly higher percentage of inadequate responders to prior bDMARDs in the seronegative RA patients (P = 0.02). Among seronegative RA, tocilizumab demonstrated a survival rate of 73.9% with a mean survival time (MST) of 76.8 months (95% CI 61-92), which was significantly higher than abatacept [37.5%, MST 37.1 months (95% CI 22-51; P = 0.01)]. Anti-TNF alpha therapy fell in the middle [50.0%, MST 63.5 months (95% CI 47-79)] but the difference was not significant. Nevertheless, seropositive RA patients did not show significantly different drug survival rates. Negative predictors of drug discontinuation were RF/ACPA positivity (HR 0.56) and sex male (HR 0.58), but treatment with abatacept (HR 1.88) or anti-TNF alpha (HR 1.79), no co-therapy with conventional DMARDs (HR 1.74), absence of bone erosions (HR 1.41) and higher HAQ (HR 1.58) were positive predictors. CONCLUSIONS: To confirm these preliminary findings and to explore the hypothesis of a distinctive therapeutic algorithm in seronegative RA, prospective studies on larger cohorts are needed.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Iannone F, Lopalco G, Cacciapaglia F, et al. Effectiveness of biological targeted therapies may discriminate seronegative from seropositive rheumatoid arthritis. Rheumatology (Oxford). 2024. PMID: 37991871. doi:10.1093/rheumatology/kead619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。